BioMarin Six Days From Print With Shorts Steady and Analysts Active

BMRN closes the week at $56.44, up 3.8%, with short interest at a one-month high and a cluster of analyst target moves arriving within 48 hours of its October 27 earnings report.

Short interest has continued building since the previous note documented the initial surge. The position now stands at 6.2% of the free float, roughly 11.9 million shares, with the one-month gain reaching 20%. The week-on-week increase of 2.6% is more modest than the 17.7% step-change recorded in the prior period, which suggests the rapid accumulation phase has slowed rather than reversed. The ORTEX short score is holding at 45.2, essentially flat across the past five sessions. Borrow remains entirely uncongestioned: cost to borrow is 0.50%, and availability at 3,122% means lenders hold more than 31 times the shares currently borrowed. Shorts have been rebuilding steadily, but they are doing so into a very liquid lending market with no squeeze mechanism in sight.

Options positioning has shifted slightly since the previous note flagged its bullish extreme. The put/call ratio was 0.29 two standard deviations below its mean as of October 14. It has since drifted back toward 0.32, roughly in line with the 20-day average of 0.33. That is not a wholesale reversal, but the strong call-side skew has moderated into something closer to neutral as the print approaches.

The analyst tape is the most active data point of the week. Morgan Stanley's Matthew Harrison trimmed his price target to $122 from $124 this morning while keeping an Overweight. JP Morgan's Jessica Fye moved in the opposite direction yesterday, nudging her target to $87 from $86, also Overweight. Cantor Fitzgerald reiterated Overweight at $86. The directional unity is notable: every change this week kept a positive rating. UBS assumed coverage on October 15 with a Buy but cut its target to $88 from $114, a significant compression that likely reflects updated VOXZOGO competitive assumptions rather than a change in fundamental view. The consensus mean target across the analyst group is $91.56, roughly 62% above the current price of $56.44. That gap is unusually wide and reflects genuine disagreement about how aggressively YUVIWEL will erode VOXZOGO's achondroplasia franchise over the next two to three years.

The bull case rests on VOXZOGO's durability as a cash engine. The franchise generated $253 million in the second quarter alone, up 15% quarter on quarter, and the settlement arrangement now converts BioMarin's largest competitor into a royalty income stream of 18% to 20% on YUVIWEL net sales through May 2030. Bears point to a balance sheet carrying roughly $3.5 billion of debt against estimated cash of around $1.9 billion by end of the third quarter of 2027, and to the execution risk around BMN 333 needing to establish real differentiation in a market that now has an approved oral alternative. The forward earnings picture has been reset aggressively higher: the factor score for 12-month forward EPS growth ranks in the 96th percentile across the universe, which captures how far consensus estimates have moved rather than confirming the company will hit them.

Wikipedia attention has spiked to a z-score of 2.4 against BioMarin's own 90-day history, the highest retail attention reading in that window. With the earnings report six days away and the stock still down 12% over the past month, the question heading into October 27 is whether the VOXZOGO royalty stream and any update on BMN 333 clinical progress are enough to close the distance between a $56 stock and a Street mean target that clusters between $86 and $122.